These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 7778056)
21. Effects of a thromboxane A2-receptor antagonist, a thromboxane synthetase inhibitor and aspirin on prostaglandin I2 production in endothelium-intact and -injured aorta of guinea pigs. Higo K; Karasawa A Jpn J Pharmacol; 1994 Dec; 66(4):471-9. PubMed ID: 7723224 [TBL] [Abstract][Full Text] [Related]
22. The thromboxane A2/prostaglandin endoperoxide receptor antagonist activity of CV-4151, a thromboxane A2 synthetase inhibitor. Imura Y; Terashita Z; Shibouta Y; Nishikawa K Eur J Pharmacol; 1988 Mar; 147(3):359-65. PubMed ID: 2967770 [TBL] [Abstract][Full Text] [Related]
24. Effect of various antiplatelet agents on acute arterial thrombosis in the rat. Bernat A; Mares AM; Defreyn G; Maffrand JP; Herbert JM Thromb Haemost; 1993 Nov; 70(5):812-6. PubMed ID: 8128439 [TBL] [Abstract][Full Text] [Related]
26. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery. Kawano KI; Fujishima K; Ikeda Y; Kondo K; Umemura K J Cereb Blood Flow Metab; 2000 Jun; 20(6):988-97. PubMed ID: 10894182 [TBL] [Abstract][Full Text] [Related]
27. Selective and nonselective inhibition of thromboxane formation. FitzGerald GA; Oates JA Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554 [TBL] [Abstract][Full Text] [Related]
28. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis. Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334 [TBL] [Abstract][Full Text] [Related]
29. The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users. Norris LA; Devitt M; Bonnar J Thromb Res; 1996 Feb; 81(4):407-17. PubMed ID: 8907290 [TBL] [Abstract][Full Text] [Related]
30. Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia. Bhatia P; Kaur G; Singh N Vascul Pharmacol; 2021 Apr; 137():106827. PubMed ID: 33346090 [TBL] [Abstract][Full Text] [Related]
31. A new approach to antithrombotic therapy--evaluation of combined therapy of thromboxane synthetase inhibitor and very low dose of aspirin. Nagatsuka K; Uyama O; Nakabayashi S; Yoneda S; Kimura K; Kamada T Stroke; 1985; 16(5):806-9. PubMed ID: 3931302 [TBL] [Abstract][Full Text] [Related]
32. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries. Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517 [TBL] [Abstract][Full Text] [Related]
33. Correlation between bleeding time and antithrombotic effect of platelet-suppressive agents in rat experimental model. Suehiro A; Oura Y; Ueda M; Kakishita E Res Commun Chem Pathol Pharmacol; 1994 Feb; 83(2):157-63. PubMed ID: 8202629 [TBL] [Abstract][Full Text] [Related]